Document Detail


Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy.
MedLine Citation:
PMID:  1511257     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-three patients with recurrent leukemia after bone marrow transplantation (BMT) underwent a second myeloablative therapy followed by second transplant between June 1977 and April 1991. Patients had either acute lymphocytic leukemia (n = 4), acute myelogenous leukemia (n = 7) or chronic myelogenous leukemia (n = 12). The median age was 29 years and the median interval between first and second BMT was 22.6 months. The second preparative therapy consisted of cyclophosphamide (200 mg/kg) and total body irradiation (1200 cGy) in nine patients and busulfan (16 mg/kg) and cyclophosphamide (120-200 mg/kg) with or without etoposide (30-60 mg/kg) in 14 patients. The same sibling donor (three syngeneic, 20 allogeneic) was used for both transplants. All patients demonstrated prompt neutrophil recovery (median 21 days) with donor-derived hematopoiesis documented in 16 of 16 evaluable patients. With a median follow-up of 24 months after second BMT, the survival, event-free survival and probability of remaining in remission at 26 months are 47%, 38% and 76% respectively. Outcome was best in patients with chronic myelogenous leukemia (7/12 survivors) and worst in patients with acute leukemia (2/11 survivors). Thus, the data would suggest that (1) selected patients with recurrent leukemia after BMT can still be cured with myeloablative therapy and second BMT, and (2) further improvements in outcome will be dependent upon the reduction of regimen-related toxicity.
Authors:
J E Wagner; G B Vogelsang; B A Zehnbauer; C A Griffin; N Shah; G W Santos
Related Documents :
24596117 - Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.
23291257 - Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation.
23858037 - The efficacy and safety of fsk0808, filgrastim biosimilar: a multicenter, non-randomize...
23559877 - A real-life experience using panitumumab in chemo-refractory metastatic colorectal canc...
23418917 - Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (ihic) f...
16285617 - Transrectal high-intensity focused ultrasound in the treatment of localized prostate ca...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  9     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-09-30     Completed Date:  1992-09-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  205-9     Citation Subset:  IM    
Affiliation:
Bone Marrow Transplantation Unit, Johns Hopkins University School of Medicine, Baltimore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Bone Marrow Transplantation / adverse effects*
Child
Child, Preschool
Female
Graft Survival
Graft vs Host Disease / etiology
Humans
Leukemia / surgery*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery
Leukemia, Myeloid, Acute / surgery
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
Recurrence
Reoperation
Grant Support
ID/Acronym/Agency:
P01 CA15396-12/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sexual satisfaction in survivors of bone marrow transplantation.
Next Document:  Propranolol for the treatment of cyclosporine-induced headaches.